Serenex, which is focused on drugs to fight cancer, is adding three executives to its management team.
Virgil “Sol” Lucas is the new vice president for clinical development; Alexander “Lex” Smith takes over as vice president of technical development; and Paul Steed is director of biology.
“Sol Lucas and Lex Smith bring over 40 years of senior level clinical and pharmaceutical development experience and leadership to the company. They will be invaluable in guiding our oncology drugs through the clinic and into the hands of patients who need them,” said Richard Kent, chief executive officer at Serenex. “We also welcome Paul Steed and his many years of research experience. We look forward to Paul adding value to our entire pipeline of products.”
Lucas worked most recently for GlaxoSmithKline. Smith’s previousy company was Fulcrum Pharma Developments. Steed worked for Amphora Discovery.